Ghrelin Regulates Glucose and Glutamate Transporters in Hypothalamic Astrocytes

Esther Fuente-Martín1,†, Cristina García-Cáceres1‡, Pilar Argente-Arizón1, Francisca Díaz1, Miriam Granado1, Alejandra Freire-Regatillo1, David Castro-González1, Maria L. Ceballos2, Laura M. Frago3, Suzanne L. Dickson3, Jesús Argente3 & Julie A. Chowen1

Hypothalamic astrocytes can respond to metabolic signals, such as leptin and insulin, to modulate adjacent neuronal circuits and systemic metabolism. Ghrelin regulates appetite, adiposity and glucose metabolism, but little is known regarding the response of astrocytes to this orexigenic hormone. We have used both *in vivo* and *in vitro* approaches to demonstrate that acylated ghrelin (acyl-ghrelin) rapidly stimulates glutamate transporter expression and glutamate uptake by astrocytes. Moreover, acyl-ghrelin rapidly reduces glucose transporter (GLUT) 2 levels and glucose uptake by these glial cells. Glutamine synthetase and lactate dehydrogenase decrease, while glycogen phosphorylase and lactate transporters increase in response to acyl-ghrelin, suggesting a change in glutamate and glucose metabolism, as well as glycogen storage by astrocytes. These effects are partially mediated through ghrelin receptor 1A (GHSR-1A) as astrocytes do not respond equally to desacyl-ghrelin, an isoform that does not activate GHSR-1A. Moreover, primary astrocyte cultures from GHSR-1A knock-out mice do not change glutamate transporter or GLUT2 levels in response to acyl-ghrelin. Our results indicate that acyl-ghrelin may mediate part of its metabolic actions through modulation of hypothalamic astrocytes and that this effect could involve astrocyte mediated changes in local glucose and glutamate metabolism that alter the signals/nutrients reaching neighboring neurons.

The coordination of energy intake and expenditure is a complex process that is influenced by both peripheral and central signals that ultimately regulate body weight and glucose homeostasis. Our understanding of the neuronal circuits controlling energy balance and metabolism has advanced considerably; however, it is only recently that glial cells have been recognized as important protagonists in this neuroendocrine process. Activation of hypothalamic microglia and astrocytes in response to high fat diet (HFD)-induced weight gain is accompanied by increased glial production of cytokines and activation of inflammatory signaling pathways in the hypothalamus1–6 which is suggested to promote central insulin/leptin resistance and metabolic disequilibrium7. This inflammatory process can be directly triggered by nutrients such as free fatty acids8, while circulating metabolic factors such as the anti-obesity hormone, leptin, can also activate glial cells2–5,9. Evidence has accumulated to substantiate an important role for glial cells in pathological responses to excess weight gain1–4,9, but their participation in the physiological control of metabolism is less well understood.

Hypothalamic astrocytes express receptors for numerous hormones involved in metabolic control, including adipostatic hormones such as leptin, but also obesity-promoting hormones such as ghrelin6,10. Leptin affects hypothalamic astrocyte morphology and their capacity to capture glucose and glutamate4,5,9 and the loss of leptin receptors specifically in astrocytes reduces the physiological anorexigenic response to this hormone and modifies the response to fasting and the appetite stimulating effect of ghrelin9, indicating the physiological importance of

1Hospital Infantil Universitario Niño Jesús, Department of Endocrinology, Instituto de Investigación La Princesa, University Autónoma of Madrid and Centro de Investigación Biomédica en Red (CIBER) de la Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain. 2Instituto Cajal, Dept. of Cellular, Molecular and Developmental Neurobiology, and CIEMAT, CSIC, Madrid, Spain. 3Dept. Physiology/Endocrine, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. **Present** address: Pancreatic Islet Development and Regeneration Unit, Department of Stem Cells, CABIMER-Andalusian Center for Molecular Biology and Regenerative Medicine, Seville, Spain. **Present** address: Helmholtz Diabetes Center, Helmholtz Zentrum München, 85764 Neuherberg, Germany. Correspondence and requests for materials should be addressed to J.A.C. (email: julieann.chowen@salud.madrid.org)
astrocytes in mediating this metabolic signal. However, little is known regarding the direct effect of ghrelin on astrocytes.

Ghrelin is mainly secreted by the stomach and its acylated form (acyl-ghrelin) promotes food intake primarily through activation of the growth hormone secretagogue receptor 1A (GHSR-1A). The metabolic effects of this hormone are largely opposite to those of leptin, which suppresses food intake and increases energy expenditure, due at least partially to their inverse actions on metabolic neuropeptide synthesis and secretion. Moreover, these two hormones rapidly induce opposite changes in the synaptic organization of hypothalamic metabolic circuits, with astrocytes most likely participating in this reorganization. Ghrelin is also involved in glucose-sensing and glucose homeostasis, a process that involves hypothalamic astrocytes and their expression of glucose transporter (GLUT)2,4,15, with aberrant hypothalamic glucose-sensing purported to be an early event in insulin resistance and type 2 diabetes.

We have recently demonstrated that chronic intracerebroventricular (icv) administration of acyl-ghrelin to rats (i) decreases the astrocytic markers, glial fibrillary acidic protein (GFAP) and vimentin, in the hypothalamus; this occurs despite ghrelin's effects to increase weight gain, and (ii) modulates cytokine production by astrocytes in vitro, suggesting a direct effect of this hormone on these glial cells. Astrocytes insure correct excitatory synaptic transmission and also protect against excitotoxicity by controlling glutamate levels in the synaptic cleft and ghrelin and its mimetics have been shown to protect against glutamate excitotoxicity. What remains completely unexplored is whether ghrelin has an acute effect on hypothalamic astrocyte morphology and glucose/glutamate transport.

To test the hypothesis that ghrelin modulates hypothalamic astrocyte function, we explored the effects of acute icv injection of acyl-ghrelin on hypothalamic astrocyte morphology and glucose and glutamate transporters. We then show that this hormone has a direct effect on glucose and glutamate uptake and metabolism in primary hypothalamic astrocyte cultures. Employing cultures of astrocytes from GHSR-1A knock-out (KO) mice and analysis of the effects of desacyl-ghrelin, an isoform that does not bind the GHSR-1A receptor, we demonstrate that at least some of the effects of acyl-ghrelin on hypothalamic astrocytes are mediated through this receptor subtype.

**Results**

**Effect of acute icv acyl-ghrelin treatment on circulating hormone levels in male rats.** There was no effect of acute acyl-ghrelin treatment on glycemia or serum insulin levels (Table 1). In control rats there was a rise in leptin levels at 24 h (F(1,26) = 6.2, p < 0.02) that did not occur in acyl-ghrelin treated rats. Injection of acyl-ghrelin icv increased circulating levels of this hormone measured at both 1 and 24 h (F(1,17) = 10.5, p < 0.005). Circulating total ghrelin levels were affected by central acyl-ghrelin administration (F(1,26) = 7.6, p < 0.01) in a time-dependent manner (F(1,26) = 6.6, p < 0.02), with levels being increased at 1 h, but not at 24 h (p < 0.005).

**Analysis of ghrelin receptor expression in astrocytes and cFos expression in response to icv acyl-ghrelin treatment.** Double immunohistochemistry for GFAP and GHSR-1A indicated that GFAP positive astrocytes express the ghrelin receptor and thus are capable of directly responding to this hormone (Fig. 1A). Administration of acyl-ghrelin resulted in increased expression of cFos in the hypothalamus (Fig. 1B), indicating a central response to this treatment. Cells expressing cFos were found lining the third ventricle (most likely ependymal cells or tanyocytes) and dispersed throughout the hypothalamus. Although some GFAP positive cells could be found to express cFOS (Fig. 1C), the majority of cFOS positive cells were GFAP negative. In the arcuate nucleus, the majority of neuropeptide Y (NPY) immunopositive neurons also expressed cFOS (Fig. 1D).

**Effect of acute icv acyl-ghrelin treatment on glial structural and synaptic proteins in the male rat hypothalamus.** As ghrelin can rapidly induce synaptic reorganization in the hypothalamus and astrocytes modify their morphology in response to other hormones, synaptic proteins and glial structural proteins and morphology were analyzed. Acyl-ghrelin had no effect at 1 h, but decreased hypothalamic GFAP levels at 24 h (F(1,11) = 7.0, p < 0.03; Fig. 2A). In concordance with these results at 1 h, no modifications in the number or morphology of GFAP positive cells in the arcuate nucleus were found (data not shown).

Vimentin is expressed in tanyocytes, as well as activated and immature astrocytes. Levels of this structural protein were modified by acyl-ghrelin (F(1,11) = 12.8, p < 0.005) in a time-dependent manner (F(1,11) = 5.3, p < 0.05), with a rise in vimentin at 1 h after acyl-ghrelin administration (Fig. 2B). This rise corresponded to increased labeling of projections radiating from the third ventricle that most likely represent tanyocytes (Fig. 2C & D), which is in accordance with cFos activation in these specialized glial cells. In control rats, glycemia and circulating hormone levels after acylated ghrelin treatment. Glycemia and circulating hormone levels in response to icv treatment with acyl-ghrelin (AG) after 1 h and 24 h. bDifferent from control (Ct1h).

| Glycemia (mg/dl) | AG1h | AG24h | ANOVA |
|-----------------|------|-------|-------|
| 97.4 ± 2.5      | 90.5 ± 3.3 | 94.6 ± 3.4 | 89.1 ± 3.1 | NS |
| Insulin (ng/ml) | 3.2 ± 0.6 | 3.3 ± 0.3 | 2.4 ± 0.5 | 2.3 ± 0.6 | NS |
| Leptin (ng/ml)  | 4.2 ± 0.5 | 3.7 ± 0.2 | 6.2 ± 0.9b | 3.7 ± 0.6b | P < 0.03 |
| AG (pg/ml)      | 245.3 ± 17.4 | 245.3 ± 17.4 | 176.1 ± 27.4 | 244.2 ± 18.9 | P < 0.04 |
| Total ghrelin (pg/ml) | 1173.4 ± 89.1 | 1173.4 ± 89.1 | 1003.6 ± 57.5 | 1353.5 ± 256.6 | P < 0.002 |

Table 1. Glycemia and hormone levels after acylated ghrelin treatment. Glycemia and circulating hormone levels in response to icv treatment with acyl-ghrelin (AG) after 1 h and 24 h. bDifferent from control (Ct1h).
Figure 1. Analysis of hypothalamic glial response to intracerebroventricular acyl-ghrelin treatment. (A) Double immunohistochemistry for glial fibrillary acidic protein (GFAP; green) and ghrelin receptor (GHSR1a; red) in the hypothalamus. Solid arrows indicate cells positive for both GFAP and GHSR1a. Open arrows indicate cells that are immunopositive only for GHSR1a. (B) Immunohistochemistry for cFos in control rats and rats that were treated icv with acyl-ghrelin (AG) for 1 hour. There was a clear increase in cFos positive cells (red) in the hypothalamus and in cells lining the 3rd ventricle (3 V) after AG treatment (solid arrow). (C) Double immunohistochemistry for GFAP and cFos. Solid arrow indicates a cell that is immunopositive for both GFAP and cFos. (D) Double immunohistochemistry for neuropeptide Y (NPY) and cFos in the arcuate nucleus. Solid errors indicate double labeled cells and the open arrow indicates a NPY neuron that is not positive for cFos. The green arrow indicates a cell only positive for cFos. ARC = arcuate nucleus, DMH = dorsomedial hypothalamus, PeN = periventricular nucleus, VMH = Ventromedial nucleus.
hypothalamic vimentin levels increased between 1 and 24 h, while levels in acyl-ghrelin treated rats did not change over time.

As an index of synaptic changes, the levels of proteins involved in synaptic organization and neurotransmitter release were measured. Synaptophysin ($F_{(1,12)} = 5.2, p < 0.05$) and syntaxin ($F_{(1,12)} = 7.7, p < 0.02$) levels were modified over time, with an increase between 1 h and 24 h in both control and acyl-ghrelin treated rats (Table 2). There was a time dependent effect of acyl-ghrelin on synaptotagmin ($F_{(1,12)} = 5.7, p < 0.03$) and SNAP25.
Acute icv acyl-ghrelin treatment modifies the levels of hypothalamic glucose and glutamate transporters in male rats. Glial cell function is substantially affected by metabolic status4,5; hence, we investigated whether acyl-ghrelin, a metabolic hormone, plays a role in this phenomenon through modification of glucose and glutamate transporters highly expressed in astrocytes. GLUT1.45, an isoform of GLUT1 expressed in most cell types in the brain including astrocytes21, increased over time (F(1,11) = 33.1, p < 0.0001; Fig. 3A), but with no effect of acyl-ghrelin. In contrast GLUT1.55, which is expressed mainly in endothelial cells of the brain microvasculature and is responsible for the transport of glucose into the brain22, was modified by acyl-ghrelin in a time dependent manner (F(1,11) = 10.5, p < 0.008) with no effect at 1 h, but increasing at 24 h (p < 0.01; Fig. 3A).
Levels of GLUT2, highly expressed in astrocytes and known to be involved in glucose sensing\(^{14,15}\), changed over time (F\(_{1,11}\) = 19.8, p < 0.001) in response to acyl-ghrelin treatment, increasing at 1 h and decreasing at 24 h (p < 0.001; Fig. 3B). GLUT3 is highly expressed in neurons\(^{21}\) and acyl-ghrelin decreased this glucose transporter at both 1 h and 24 h after treatment (p < 0.001; Fig. 3C).

Acyl-ghrelin differentially modulated both isoforms of the glutamate transporter GLT1, which are expressed almost exclusively in astrocytes\(^{23}\). Levels of the GLT1.51 isoform rose at 1 h (p < 0.05; Fig. 3D), with no effect at 24 h, while GLT1.75 did not change. Glutamate aspartate transporter (GLAST) levels changed over time in response to acyl-ghrelin (F\(_{1,11}\) = 15.1, p < 0.003), being increased at 1 h and then decreasing to control levels at 24 h (p < 0.0001; Fig. 3E).

Glutamate is metabolized to glutamine by the astrocyte-specific enzyme glutamine synthetase\(^{24}\). Levels of this enzyme were decreased by acyl-ghrelin at both 1 h and 24 h (F\(_{1,11}\) = 34.0, p < 0.0001; Fig 3F), suggesting a possible decrease in the levels of glutamate made available to neurons. In contrast, glutamate decarboxylase (GAD)\(_{65}\), which catalyzes the decarboxylation of glutamate to GABA in neurons, had a time-dependent increase in response to acyl-ghrelin (F\(_{1,12}\) = 16.2, p < 0.002; Fig. 3G), rising at 1 h and returning to control levels by 24 h (p < 0.003).

As the astrocyte-neuronal lactate shuttle has been implicated in the regulation of glucose homeostasis\(^{25}\), we analyzed the levels of monocarboxylate transporters (MCT) that transport both lactate and pyruvate. Acyl-ghrelin treatment did not affect MCT1, which is widely expressed in the brain including both neurons and astrocytes (Ct1h:100 ± 8.3, AG1h: 113.6 ± 11.6, Ct24h: 115.6 ± 5.5, AG24h: 93.4 ± 22.3% Ct1h) or MCT2 (Ct1h:100 ± 11.2, AG1h: 94.5 ± 28.6, Ct24h: 138.8 ± 39.0, AG24h: 190.4 ± 71.9% Ct1h). MCT4 is expressed in metabolically active cells and in the brain it is mainly found in astrocytes\(^{26}\). Levels of MCT4 increased 1 h after treatment with acyl-ghrelin and returned to basal levels at 24 h (Fig. 3H).

**Changes in hypothalamic glucose and glutamate transporters in response to chronic acyl-ghrelin treatment are seen in ad libitum but not pair-fed rats.** As continuous exposure to increased levels of acyl-ghrelin causes metabolic changes that could be involved in the glial responses observed at 24 h, we determined how chronic exposure to increased central acyl-ghrelin affects hypothalamic glucose and glutamate transporters. This was compared to the response in acyl-ghrelin treated rats that were pair-fed to control rats in order to limit the metabolic effects of acyl-ghrelin induced food intake. There was no effect of chronic acyl-ghrelin exposure on GLUT1 levels (data not shown), while GLUT2 (p < 0.01; Fig. 4A) and GLUT3 (p < 0.05; Fig. 4B) were decreased by acyl-ghrelin in rats allowed to eat ad libitum. However, acyl-ghrelin had no effect on these parameters in pair-fed rats. Chronic acyl-ghrelin treatment increased both isoforms of GLT1 (p < 0.05; Fig. 4C) and GLAST (p < 0.01; Fig. 4D), but again only in ad libitum fed rats. Thus, the effects of long-term acyl-ghrelin treatment on glucose and glutamate transporters appear to be related to the changes in metabolic parameters induced by this hormone, including weight gain, when the rats are allowed to eat ad libitum\(^{10}\).

**Acyl-ghrelin rapidly modifies glucose and glutamate uptake into rat hypothalamic astrocytes.** Leptin has time-dependent effects on GLUT2 and GLAST levels and glucose and glutamate uptake into hypothalamic astrocytes in vitro\(^{4}\); therefore, we analyzed these parameters after acyl-ghrelin treatment for 1 h and 24 h. Total GLUT2 levels were decreased at 1 h and increased at 24 h (p < 0.001; Fig. 5A). This is consistent with the observation that acyl-ghrelin treatment rapidly decreased glucose uptake in primary astrocyte cultures that increased to control levels with 24 h exposure (p < 0.05; Fig. 5B). GLUT1 and GLUT3 levels were unaffected by acyl-ghrelin in astrocyte cultures (data not shown). As glucokinase is important for central glucose-sensing\(^{27}\) and this enzyme is expressed in glial cells\(^{28}\), we determine whether acyl-ghrelin modulated the expression of this enzyme in hypothalamic astrocytes. No significant effect of AG was found (Ct1h:100 ± 15.3, AG1h: 103.3 ± 21.9, Ct24h: 144.6 ± 40.0, AG24h: 130.6 ± 22.0% Ct1h).

GLAST levels were increased in astrocytes in vitro at both 1 h and 24 h after exposure to acyl-ghrelin (p < 0.01; Fig. 5C), with no significant effect on GLUT1 levels (data not shown). Acyl-ghrelin exposure resulted in rapid glutamate uptake into astrocytes (p < 0.05; Fig. 5D) that then decreased after 24 h of treatment. Glutamate concentrations decreased in the culture media at 24 h after acyl-ghrelin treatment (p < 0.001; Fig. 5E), with no significant effect seen at 1 h or 2 h (data not shown).

Although glutamate uptake into astrocytes rose, glutamine synthetase levels, which catalyzes the conversion of glutamate to glutamine\(^{4}\), were unchanged at 1 h and decreased at 24 h after treatment (p < 0.05; Fig. 5F). This suggests that although acyl-ghrelin stimulates astrocytes to rapidly take-up glutamate, this process may not be accompanied by increased conversion of glutamate to glutamine. The glutamate-glutamine cycle is a physiological process in situations of increased glutamate neurotransmission whereby astrocytes produce glutamine that is then supplied to neurons in order for these cells to replenish their glutamate stores\(^{29}\). Glutamate uptake into astrocytes also stimulates lactate production, at least in vitro\(^{30}\), and we found that the acyl-ghrelin stimulated increase in glutamate uptake was associated with increased expression of lactate dehydrogenase at 1 h (p < 0.003; Fig. 5G). This was associated with a rise in MCT4 levels at 1 h (p < 0.001; Fig. 5H), suggesting a rapid increase in lactate transport by astrocytes. However, lactate levels in the culture media did not change in response to acyl-ghrelin treatment, but increased with time (p < 0.0005; Fig. 5I). Protein levels of MCT1 were undetectable by Western blotting.

Astrocytes store glycogen that can be mobilized in situations of energy deficit\(^{31}\). The mRNA levels of glycogen phosphorylase, the rate limiting enzyme in glycogenolysis\(^{32}\), were stimulated by acyl-ghrelin (p < 0.0003) in a time dependant manner (p < 0.01), reaching significance at 24 h (Fig. 5J). Although there was a tendency to decrease in response to acyl-ghrelin at 1 h, the cellular glycogen levels in astrocytes did not change significantly (Fig. 5K). Insulin stimulated glycogen storage in astrocytes (154% of control levels at 24 h), as previously reported\(^{33}\).
Acyl-ghrelin modifies glucose and glutamate transporters in astrocytes from mice through the GHSR-1A receptor. To determine whether the direct effect of acyl-ghrelin on astrocytes is mediated through GHSR-1A, primary cultures from WT and GHSR-1A KO mice were employed. Immunoreactive GHSR-1A could be detected in WT cultures, but not in those from KO mice (Fig. 6A). There was no effect of acyl-ghrelin on GFAP levels in cultures from WT or GHSR-1A KO mice (Fig. 6B). In contrast, acyl-ghrelin increased GLUT2 (p < 0.05; Fig. 6C) and GLAST (p < 0.05; Fig. 6D) in WT cultures, but had no effect in astrocytes cultured from GHSR-1A KO mice, suggesting that this effect is mediated through GHSR-1A. Although there was no effect of acyl-ghrelin on GFAP in astrocyte cultures from WT or GHSR-1A KO mice, we have previously reported that this hormone stimulates GFAP in astrocytes from rats10, indicating a possible difference between species.

We next treated rat hypothalamic astrocyte cultures with acyl-ghrelin or desacyl-ghrelin to determine whether the stimulatory effect on GFAP and glucose and glutamate transporters in rats is specific to acyl-ghrelin. Both ghrelin isoforms stimulated GFAP levels in these cultures (p < 0.0001; Fig. 6E), suggesting that this response is not mediated, at least exclusively, through GHSR-1A in rat astrocytes. In contrast, GLUT2 (p < 0.005; Fig. 6F) and GLAST (p < 0.05; Fig. 6G) were increased by acyl-ghrelin but not by desacyl-ghrelin, corroborating the results in the KO mice indicating that this effect is likely mediated through GHSR-1A.

Discussion
It is becoming increasingly clear that astrocytes have a multifactorial participation in the neuroendocrine control of metabolism, with these glial cells having both physiological and pathophysiological actions4,34,35. Here we show that the orexigenic hormone acyl-ghrelin can rapidly modulate hypothalamic levels of glucose and glutamate transporters highly expressed in astrocytes, both in vitro and in vivo, and the ability of these glial cells to transport glucose and glutamate in vitro. This suggests some effects of this hormone on metabolic circuits could be
Figure 5. Response of hypothalamic astrocyte-enriched cultures to acyl-ghrelin treatment. Relative levels of (A) glucose transporter (GLUT)2, (B) glucose uptake, (C) glutamate-aspartate transporter (GLAST), and (D) glutamate uptake in primary astrocyte-enriched cultures from the hypothalamus of male Wistar rats treated with acyl-ghrelin (AG) or vehicle (Ct) for 1 h or 24 h. (E) Glutamate levels in the media of primary astrocyte cultures decreased after 24 h exposure to AG. Relative levels of (F) glutamine synthetase, (G) lactate dehydrogenase, (H) monocarboxylate transporter (MCT)4, (I) glycogen phosphorylase and (K) intracellular glycogen content were measured in primary astrocyte-enriched cultures from the hypothalamus of male Wistar rats treated with acyl-ghrelin (AG) or vehicle (Ct) for 1 h or 24 h. Lactate levels (I) were measured in the media of primary astrocyte cultures after 1, 3 or 24 h exposure to AG. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, NS = not significant. Representative Western blots are from the same gel although samples were not always contiguous within the gel.
mediated through astrocytic modification of local glucose and glutamate levels, which could in turn affect neuronal excitability and activity, as well as survival.

Glucose is the main fuel source for the brain and astrocytes play an important role in its uptake and transport within the brain\textsuperscript{36}. Glucose is transported into the CNS through GLUT1 located in the endfeet of astrocytes.
surrounding capillaries, but acyl-ghrelin did not modify the astrocytic isof orm of this transporter in vivo or in vitro, although it would be of interest to determine levels specifically in the endfeet of these glial cells. In neurons, glucose uptake is primarily mediated through GLUT3 and acyl-ghrelin rapidly decreased hypothalamic levels of this transporter. Hypoglycemia, which stimulates ghrelin secretion, also reduces hypothalamic GLUT3 expression. Thus, acyl-ghrelin could be involved in signaling a reduction in glucose levels to the hypothalamus in situations of negative energy balance such as fasting, inducing a switch to alternative energy sources.

Astrocytes generate lactate that can then be used by neighboring neurons as an alternative energy source and this is especially important in situations of low glucose availability. An acyl-ghrelin induced rise in lactate availability to neurons is suggested by its stimulation of lactate dehydrogenase and MCT4 levels both in vivo and in vitro. Moreover, an increase in glycogen phosphorylase indicates that acyl-ghrelin stimulates the hydrolysis of glycogen stores in astrocytes, which can contribute to a rise in lactate production, which could also result from the rise in glutamate uptake; however, we saw no significant change in glycogen levels suggesting that they may be rapidly restored. Although the rise in MCT4 levels suggests an increase in lactate transport, we detected no effect of acyl-ghrelin on extracellular lactate concentrations. Lactate levels increased dramatically overtime in the media from all cultures; however, as the concentration gradient in the in vitro system favored the outflow of lactate, the possible contribution of ghrelin to increased lactate secretion could have been masked. Lactate can also be metabolized back to pyruvate, which is also transported by MCT4. Although more studies are clearly necessary to determine how acyl-ghrelin directly modifies astrocyte metabolism and transport of nutrients to neurons, these cells do respond to this orexigenic signal. Hypothalamic GLUT3 levels were decreased at 24 h after acute acyl-ghrelin treatment and with chronic iv acyl-ghrelin treatment. However, this long-term suppression may not be a direct effect of acyl-ghrelin, as GLUT3 returns to control levels when rats are pair-fed even though circulating acyl-ghrelin levels remain high in these animals. We presented here, one might speculate that direct acyl-ghrelin modulation of astrocyte GLUT2 levels and glucose transport could impact on the glucose-sensing mechanism. In astrocyte cultures acyl-ghrelin rapidly decreased GLUT2 levels and this was associated with decreased glucose uptake. These parameters increased or returned to control levels by 24 h of exposure. This time-dependent effect could indicate the more acute effects of ghrelin as observed in the physiological pre-prandial rise in its circulating levels versus prolonged hyperghrelinemia, as in fasting or starvation. The preprandial rise in ghrelin is coincident with increased glycemia and a decrease in insulin before food intake commences. A rapid decline in GLUT2 could decrease the glucose-sensing ability of astrocytes that would increase ingestion, which is one function of ghrelin. Increased ghrelin during starvation is involved in maintaining glucose levels. However, the in vitro effects of acyl-ghrelin on GLUT2 levels in astrocyte cultures were opposite to those seen in vivo. GLUT2 could be regulated differently in other cell types, such as neurons, or other glial cells that have been shown to respond to ghrelin, including microglia and oligodendrocytes. Moreover, indirect effects of acyl-ghrelin on hypothalamic astrocytes, such as stimulation of gliotransmitter release, have also been described. Energy transport and metabolism are tightly coupled between astrocytes and neurons and this cross-talk is lacking in the in vitro system, thus modifying the normal temporal changes in inputs received by these glial cells.

Tanycytes also express GLUT2 and appear to respond rapidly to acyl-ghrelin in vivo, as we found cFos expression in cells lining the 3 V and vimentin labeled projections from the 3 V were increased with no indication of vimentin positive astrocytes being found. Tanycytes occupy a strategic location for the transport of metabolic factors to the hypothalamus, are a source of progenitor cells for the regeneration of hypothalamic metabolic circuits and are involved in glucose sensing. Whether ghrelin mediates any of these metabolic functions of tanycytes deserves future investigation, but it is of note that tanycytes were recently demonstrated to transport both acyl-ghrelin and desacyl-ghrelin across the blood-brain barrier, similar to what has also been reported for leptin entry into the brain. Thus, these specialized cells appear to play an important regulatory role in the transport of metabolic hormones. Moreover, a decreased ability of tanycytes to transport ghrelin could possibly contribute to some situations of increased weight gain.

Vimentin increased between 1 and 24 hours in control rats. Hypothalamic levels of this structural protein are modulated by melatonin, glucocorticoids and thyroid hormone. Levels of these hormones fluctuate throughout the day; hence, it is possible that hypothalamic vimentin levels are physiologically modulated in a diurnal or circadian fashion. However, this possibility, as well as whether AG participates in generating a rhythmic expression of vimentin, remains to be determined.

Acyl-ghrelin also stimulated rapid glutamate uptake by astrocytes in vitro. Glutamate transport by astrocytes not only modulates synaptic transmission and produces neuroprotection, but it also activates glycolysis in these cells, increasing both the production and release of lactate to be used as an alternative fuel source for neurons during increased activation. This is in concordance with the acyl-ghrelin induced increase in the expression of MCT4 and lactate dehydrogenase, as discussed above. Glutamate transporters are highly expressed on astrocytes, with GLT1 being found almost exclusively in astrocytes and GLAST in astrocytes and other glial cells. Both GLT1 and GLAST were increased rapidly by acyl-ghrelin in vivo, but in vitro this effect was only seen on GLAST. These two glutamate transporter are involved in different functions, such as neurotransmission versus neuroprotection, within the same tissue and thus, the mechanisms that control their expression may also differ.
Ghrelin potentiates glutamate release to activate NPY/AgRP neurons and, as shown here, also rapidly stimulates the uptake of glutamate by astrocytes, which would function to avoid excess excitability and excitotoxicity to neighbouring neurons. Indeed, ghrelin and its mimetics to protect against glutamate excitotoxicity.

Within astrocytes, glutamate can be metabolized to glutamine via glutamine synthetase or be shuttled into the tricarboxylic acid cycle (TCA). Glutamine released by astrocytes can be taken-up by neurons where it can be reconverted to glutamate via glutaminase enzymatic actions. This astrocyte-mediated glutamate recycling is coupled to glucose glycolysis where the resulting lactate is then released for neuronal uptake and oxidation. Although glutamate uptake is stimulated by acyl-ghrelin, glutamine synthetase levels were decreased both in vivo and in vitro, suggesting that glutamate could be shuttled into the TCA cycle. Indeed, when external glutamate levels are low the glutamine synthetase pathway is favored, but when glutamate concentrations are high, oxidative processes are recruited, with considerable glutamate being consumed via astrocytic malic enzyme. Glutamate consumption in the brain also increases in hypoglycemic states when ghrelin levels would be increased. Acute icv acyl-ghrelin administration also stimulated GAD levels, suggesting increased GABA production. Indeed, ghrelin stimulates GABA release in the hypothalamic through astrocyte release of ATP. Likewise, fasting increases hypothalamic production of GABA, possibly through increased ghrelin secretion. Together these results suggest that astrocytes participate in acyl-ghrelin’s effects on hypothalamic synaptic transmission, and possibly neuronal metabolism.

Rapid modifications in synaptic inputs in the arcuate nucleus occur in response to ghrelin. Here we found synaptotagmin-1 to be decreased and SNAP25 to be increased within one hour after icv acyl-ghrelin injection, with both returning to control levels at 24 h. Synaptotagmin-1 acts as a calcium-sensor in Ca2+-dependent release of neurotransmitter vesicles and is important for the local functioning of GABAergic/glutamatergic reciprocal connections. The rapid increase in the membrane SNARE protein SNAP25 could indicate an increase in secretory vesicle turn-over. As PSD95 is an integral postsynaptic component of glutamatergic synapses, a reduction in this protein after 24 h of exposure to acyl-ghrelin suggests a reduction in excitatory inputs in the hypothalamus, similar to what was reported by Pinto and colleagues.

The effects of acyl-ghrelin are mediated at least in part through GHSR-1A, as acyl-ghrelin did not modulate GLUT2 or GLAST levels in astrocyte cultures from mice lacking this receptor. Moreover, deacyl-ghrelin did not induce these effects in rat hypothalamic astrocytes. In contrast, both acyl- and deacyl-ghrelin stimulated GFAP levels in vitro, indicating a GHSR-1A independent effect. Glucose and glutamate transport in response to acyl-ghrelin were not measured in mouse astrocytes. Although one might expect similar responses as those observed in rats, given that changes in transporters were similar, this has not been demonstrated.

The results reported here add to the expanding functions attributed to astrocytes in the neuroendocrine control of metabolism. Rapid changes in astrocyte functions in response to metabolic hormones appear to play an important role in the normal physiology of metabolic circuits. Astrocytic responses change with prolonged exposure to metabolic hormones, indicating that they could also mediate some of the pathophysiological effects of prolonged exposure to these substances. Thus, in order to completely understand how metabolic circuits work and to target them for treatment of conditions such as obesity, the functions of glial cells must also be taken into consideration.

Materials and Methods

Ethical statement. All experiments were designed according to the European Union and local laws (Royal decree: 53/2013, EU Council Directive: 2010/63/EU) for animal care. The studies were approved by the appropriate local institutional ethical committees (The Scientific Committee of the Hospital Infantil Universitario Niño Jesús, The Committee for Animal Welfare of the Universidad Autónoma de Madrid, and The Ethics Committee of the University of Gothenburg).

Acute icv acyl-ghrelin treatment of adult male rats. Adult male Wistar rats (250–300 g; n = 16/group; Harlan Interfaunaiberica S.A., Barcelona, Spain) were allowed to acclimate for 1 week before surgeries were performed. Rats were anesthetized (0.02 ml ketamine per 100 g of body weight (bw) and 0.04 ml xylazine per 100 g bw) and a cannula attached to a catheter was implanted in the left lateral cerebral ventricle (0.08 mm anteroposterior, 0.16 mm lateral from Bregma). Twenty-four hours after surgery, rats received either acyl-ghrelin (2 μg in 5 μl; ANASPEC, Fremont, CA, USA) or saline (5 μl; Ct). Rats were killed by decapitation at either 1 h or 24 h after the injection. The brains were removed, post-fixed in the same fixative overnight at 4 °C and stored in cryoprotection solution (30% sucrose, 30% ethylene glycol, in PB) at −20 °C until processed.

To determine the acute effects of ghrelin on astrocyte morphology and cellular activation in response to treatment, acyl-ghrelin or saline treated rats (n = 5) were perfused transcardially (4% paraformaldehyde, pH 7.4) under pentobarbital anesthesia (1 mg/kg) 1 h after treatment. The brains were removed, post-fixed in the same fixative overnight at 4 °C and stored in cryoprotection solution (30% sucrose, 30% ethylene glycol, in PB) at −20 °C until processed.

Chronic icv acyl-ghrelin treatment. To compare the rapid effects with the long-term effects of acyl-ghrelin on hypothalamic glutamate and glucose transporters, our study included rats that were treated icv with acyl-ghrelin for two weeks. The metabolic parameters in these rats have been reported previously.

Briefly, adult male Wistar rats were treated as in the acute injection study except that a minipump (Alzet, Durect Co, Canada) that delivered either 5 μg/day (0.208 μg/hour) acyl-ghrelin or saline for 14 days was connected to the cannula that was implanted in the left lateral ventricle. All rats were given free access to food and water except the pair-fed acyl-ghrelin-treated group that received the same amount of food that the controls had consumed the previous day.

Correct placement of the cannula was confirmed when the brains were processed.
Primary astrocyte cultures from Wistar rats. Primary astrocyte cultures of the hypothalamus from
two-day-old male Wistar rats were prepared as previously described4,4,11. Cultures were serum starved for 24 h
and then treated with 100 nM of recombinant rat acyl-ghrelin or vehicle for 1, 3 or 24 h. Each treatment was done in
triplet in each experiment and each experiment repeated 4–6 times (n = 4–6).

to determine the specificity of the response to acyl-ghrelin and to determine if this hormone was acting
through GHSR-1A, in a set of experiments cultures were treated with vehicle, acyl-ghrelin (100 nM) or desacyl-
ated (desacyl)-ghrelin (100 nM), which does not bind to GHSR-1A4, for 24 h.

Primary astrocyte cultures from WT and GHSR-1A KO mice. Hypothalami were removed from
two-day-old wild-type or KO male littermates from GHSR-1A KO mice46 and processed as above except that
each hypothalamus was seeded separately to allow for the posterior determination of genotype. For immunocy-
tochemistry, a sterilized round coverslip was placed in the culture wells before plating the cells. These cells were
then processed for immunolabeling as stated below.

Dose response curves were performed to determine the appropriate dose of acyl-ghrelin to be used. The lowest
dose with the maximum effect was selected.

Protein extraction and Western blotting. The hypothalamic and primary astrocyte cultures were pro-
cessed and protein concentration determined as previously reported4. Western blotting was performed as pre-
viously described4,4. The sources of the primary antibodies employed were as follows: GFAP (cat.# G9269) and
vimentin (cat.# V6389) from Sigma, GLUT1 (cat.# GT12-A), GLUT2 (cat.# GT21-A), GLUT3 (cat.# GT31-A)
and GLAST (cat.# GLAST11-A) from Alpha Diagnostic International (San Antonio, TX), GLT1 (cat.# PA3-
040A) from Affinity BioReagents (Golden, CO), GAD65/67 (cat.# AB1511), MCT1 (cat.# AB3550) and MCT4
(AB3314P) from Millipore, glutamine synthetase (cat.# G7121) from US Biological (Swampscott, MA), synapo-
physin (cat.# RM-91150) from ThermoScientific (Rockford, IL) and synapsin I (cat.# 574778), synaptotagmin
(cat.# 573826), syntaxin (cat.# 574784), SNAP25 (cat.# 487912) and PSD95 (cat.# 529541) from Calbiochem
(San Diego, CA), Anti-MCT2 (cat.# sc-50323) and actin (cat.# sc-1616) from Santa Cruz Biotechnology (Santa
Cruz, CA) and anti-glyceraldehyde 3-phosphate dehydrogenase [GAPDH (cat.# 54953) from ANASPEC] were
used to normalize sample loading variability. Secondary antibodies conjugated with peroxidase were from Pierce
Biotechnology (Rockford, IL). Bound peroxidase activity was visualized by chemiluminescence and quantified
by densitometry using a Kodak Gel Logic 1500 Image Analysis system and Molecular Imaging Software, version
4.0 (Rochester, NY). All data are normalized to control values on each gel.

Immunohistochemistry. Coronal brain sections (40 μm) were cut on a vibratome and stored in cryoprotect-
sion solution at −20°C. For immunohistochemistry, brain sections containing the hypothalamic arcuate nucleus
were washed in PB, incubated in 50% methanol containing 3% hydrogen peroxide for 20 min and then washed
twice for 20 min in 0.1 M PB with 0.3% bovine serum albumin and 0.3% Triton X-100. This buffer was also used in
the subsequent washes and incubations. Free-floating sections were incubated overnight at 4°C with anti-GFAP
or anti-vimentin at a dilution of 1:500, washed twice and incubated for 2 hr with horseradish peroxidase con-
jugated goat anti-mouse IgG (Pierce Biotechnology, 1:500) at RT. Peroxidase activity was revealed with 0.01%
hydrogen peroxide, using 3,3’-diaminobenzidine as the chromagen. Immunostaining was absent when the pri-
mary antibody was omitted. All sections from both groups were assayed in parallel.

For immunofluorescent staining, tissue sections were rinsed in PB and then incubated in the same buffer as
above. The free-floating sections were incubated 72 h with anti-GFAP (1:500), anti-GHSR1 (cat.# sc-10362
Santa Cruz Biotechnology, 1:200), anti-cFOS (cat.# sc-52c; Santa Cruz Biotechnology, 1:500), anti-NPY (cat.#
ABS 028-08-02 ThermoFisher, 1:500) or a combination of these antibodies. Astrocyte cultures were first fixed
with paraformaldehyde (4%) and rinsed in PB. The antibodies (anti-GFAP and anti-GHSR1) and washes were
added directly in the culture wells. For GFAP detection, sections were incubated with anti-mouse Alexa Fluor
488 (1:1000, Molecular Probes). For GHSR1 and cFOS detection, sections were incubated with biotin labeled
anti-goat or anti-rabbit IgG (1:1000, Thermo Scientific), respectively, for 2 h followed by incubation with streptavidin Alexa Fluor 633 (1:1000, Molecular Probes) for 2 h. Immunofluorescence was visualized with a scan-
ning confocal microscope. The specificity of the GHSR1 antibody was previously tested67 with these authors
showing no labeling by this antibody in GHSR1 KO mice.

Analysis of glial cell morphology. Six sections/rat, distributed from −2.3 to −3.3 mm from Bregma con-
taining the arcuate nucleus were analyzed. Images from fifteen rectangular fields of the arcuate nucleus corre-
sponding to an area of 19.5 mm² in each section were captured at 40X by using a digital camera and Image-Pro
Plus software (Media Cybernetics Inc, Silver Spring, MD). The number of GFAP+ cells per field, the number of
projection per cell and the mean projection length were determined by using ImageJ. All morphometric analyses
were performed without previous knowledge of the experimental group from which the sections were obtained.

Real time-PCR. Extraction of total RNA and real time-PCR were carried out in hypothalamic astrocyte cul-
tures as previously described5. Predesigned primers from Applied Biotechnology were used to measure relative
expression levels of lactate dehydrogenase (ldha, Rn00820751), glucokinase (Rn00561265) and glycogen phos-
phorylase (pygb, Rn01536623) and 18 s (rps18, Rn01428915) was used as the internal control.

Glycogen content in astrocyte cultures. Cellular glycogen content in response to acyl-ghrelin was measured
in hypothalamic astrocytes according to the manufacturer’s instructions (Sigma). Insulin treatment (50 nM)
was used as a positive control.
Glutamate and lactate concentrations in cell culture media. After incubation of primary hypothalamic astrocyte cultures with acyl-ghrelin or vehicle for 1, 3 or 24 h as described above, 1 ml of media was removed from each culture and lyophilized (n = 3 independent experiments). Glutamate (BioVision, Mountain View, CA, USA) and lactate (EnsyChrom, BioAssay Systems, Hayward, CA, USA) determinations were performed following the manufacturers’ instructions.

Glutamate uptake by astrocytes. 8,36-2-deoxy-glucose ([3H]-2-DG) uptake experiments were conducted as previously described4. Astrocytes (+) were either treated with acyl-ghrelin (100 nM) for 24 h or added for 10 min during the preincubation period and maintained during the incubation. Blanks, which were similarly processed but incubated at 0°C, accounted for 20% of the radioactivity in control cultures and this was subtracted from all measurements. All experiments were performed in triplicate and using primary astrocyte cultures from at least 5 different male pups.

Glutamate uptake by astrocytes. Glutamate uptake was performed as previously described4. Blanks, which were similarly processed but incubated at 0°C, accounted for 20% of the radioactivity in control cultures and this was subtracted from all measurements. All experiments were performed in triplicate and using primary astrocyte cultures from at least 5 different male pups.

Statistical analysis. All data are presented as mean ± SEM. A two-tailed Student’s t test was used for comparison between 2 groups. Two-way ANOVA was used to determine the effect of acyl-ghrelin over time. Scheffe’s F test was used for posthoc analysis. The values were considered significantly different when the p value was lower than 0.05. All Western blotting results are reported as the percent of the control value. In vitro studies the n represents the number of individual experiments performed.

References
1. Horvath, T. L. et al. Synaptic input organization of the melanocortin system predicts diet-induced hypothalamic reactive gliosis and obesity. Proc Natl Acad Sci USA 107, 14875–14880, doi:10.1073/pnas.1004282107 (2010).
2. Thaler, J. P. et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest 122, 153–162, doi:10.1172/JCI96600 (2012).
3. Gao, Y. et al. Hormones and diet, but not body weight, control hypothalamic microglial activity. Glia 62, 17–25, doi:10.1002/glia.22580 (2014).
4. Fuente-Martin, E. et al. Leptin regulates glutamate and glucose transporters in hypothalamic astrocytes. J Neurosci 122, 3900–3913, doi:10.1172/JCI4102 (2012).
5. Garcia-Caceres, C. et al. Differential acute and chronic effects of leptin on hypothalamic astrocyte morphology and synaptic protein levels. Endocrynology 152, 1809–1818, doi:10.1210/en.2010-1252 (2011).
6. Hsouch, H. et al. Obesity induces functional astrocytic leptin receptors in hypothalamus. Brain 132, 889–902, doi:10.1093/brain/awp029 (2009).
7. Cal, D. & Liu, T. Inflammatory cause of metabolic syndrome via brain stress and NF-kappaB. Aging (Albany NY) 4, 98–115 (2012).
8. Milanski, M. et al. Saturated fatty acids produce an inflammatory response predominantly through the activation of TLR4 signaling in hypothalamus: implications for the pathogenesis of obesity. J Neurosci 29, 359–370, doi:10.1523/JNEUROSCI.2760-08.2009 (2009).
9. Kim, J. G. et al. Leptin signaling in astrocytes regulates hypothalamic neuronal circuits and feeding. Nat Neurosci 17, 908–910, doi:10.1038/nn.3725 (2014).
10. Garcia-Caceres, C. et al. The opposing effects of ghrelin on hypothalamic and systemic inflammatory processes are modulated by its acylation status and food intake in male rats. Endocrinology 155, 2688–2690, doi:10.1210/en.2014-1074 (2014).
11. Muller, T. D. et al. Ghrelin. Mol Metab 4, 437–460, doi:10.1016/j.molmet.2015.03.005 (2015).
12. Pinto, S. et al. Rapid rewiring of arcuate nucleus feeding circuits by leptin. Science 304, 110–115, doi:10.1126/science.1089459 (2004).
13. Briggs, D. I. & Andrews, Z. B. A recent update on the role of ghrelin in glucose homeostasis. Curr Diabetes Rev 7, 201–207 (2011).
14. Leolup, C., Oroso, M., Serradas, P., Nicolaidis, S. & Penicaud, L. Specific inhibition of GLUT2 in arcuate nucleus by antisense oligonucleotides suppresses nervous control of insulin secretion. Brain Res Mol Brain Res 57, 275–280 (1998).
15. Bady, I. et al. Evidence from glu2-null mice that glucose is a critical physiological regulator of feeding. Diabetes 55, 988–995 (2006).
16. Parton, L. et al. Glucose sensing by POMC neurons regulates glucose homeostasis and is impaired in obesity. Nature 449, 228–232, doi:10.1038/nature06098 (2007).
17. Rothstein, J. D. et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16, 675–686 (1996).
18. Delgado-Rubin, A., Chowen, J. A., Argente, J. & Frajo, L. M. Growth hormone-releasing peptide 6 protection of hypothalamic neurons from glutamate excitotoxicity is caspase independent and not mediated by insulin-like growth factor I. Eur J Neurosci 29, 2115–2124, doi:10.1111/j.1460-9568.2009.06770.x (2009).
19. Lee, S., Kim, Y., Li, E. & Park, S. Ghrelin protects spinal cord motoneurons against chronic glutamate excitotoxicity by inhibiting microglial activation. Korean J Physiol Pharmacol 16, 43–48, doi:10.4196/kjpp.2012.16.1.43 (2012).
20. Elmqist, J. K., Swanson, J. J., Sakaguchi, D. S., Ross, L. R. & Jacobson, C. D. Developmental distribution of GFAP and vimentin in the developing and mature CNS. J Neurosci 27, 153–162, doi:10.1523/JNEUROSCI.2760-08.2009 (2004).
21. Vannucci, S. J. et al. Glucose transporter proteins in brain: delivery of glucose to neurons and glia. Glia 21, 2–21 (1997).
22. De Giorgis, V. & Veggioit, P. GLUT1 deficiency syndrome 2013: current state of the art. Seizure 22, 803–811, doi:10.1016/j.seizure.2013.07.003 (2013).
23. Regan, M. R. et al. Variations in promoter activity reveal a differential expression pattern of glucose transporters by glia in the developing and mature CNS. J Neurosci 27, 6607–6619, doi:10.1523/JNEUROSCI.0790-07.2007 (2007).
24. Martinez-Hernandez, A., Bell, K. P. & Norenberg, M. D. Glutamine synthetase: glial localization in brain. Science 195, 1356–1358 (1977).
25. Arrieta-Cruz, I., Su, Y., Knight, C. M., Lam, T. K. & Gutierrez-Juarez, R. Evidence for a role of proline and hypothalamic astrocytes in the regulation of glucose metabolism in rats. Diabetes 62, 1152–1158, doi:10.2337/db12-0228 (2013).
26. Raddi, A., Boulland, J. L., Halestrap, A. P., Ottersen, O. P. & Bergersen, L. Highly differential expression of the monocarboxylate transporters MCT2 and MCT4 in the developing rat brain. Neuroscience 122, 677–688 (2003).
27. Dunn-Meynell, A. A., Routh, V. H., Kang, L., Gaspers, L. & Levin, B. E. Glucokinease is the likely mediator of gluosensing in both glucose-excited and glucose-inhibited central neurons. Diabetes 51, 2056–2065 (2002).
Acknowledgements

The authors would like to thank Sandra Canelles for the excellent technical support. This work was funded by grants from Fondo de Investigación Sanitaria (PI100747; PI1302195), Ministerio de Ciencia e Innovación (BFU2011–27492; BFU2014-51856-C2-2-R) and Fondos FEDER, Centro de Investigación Biomédica en Red Fisiopatología de Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, and Fundación de Endocrinología y Nutrición. SD was funded by the Swedish Research Council (Vetenskapsrådet grant 2012–1758), Läkarutbildningsavtalet Göteborg grant at Sahlgrenska Hospital (ALFGBG-138741, The European Union Seventh Framework Programme under Grant Agreement 607310, Nudge-it). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions

E.F.M., C.G.C., S.L.D., J.A. and J.A.C. conceived and designed the experiments; E.F.M., C.G.C., P.A.A., F.D., M.G., A.F.R., D.C.G. and M.L.C. performed the experiments; E.F.M., L.M.F., S.L.D., J.A. and J.A.C. analyzed the data; M.L.C., S.L.D., J.A. and J.A.C. contributed reagents/materials/analysis tools; E.F.M., J.A. and J.A.C. wrote the paper. All authors reviewed the manuscript.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Fuente-Martín, E. et al. Ghrelin Regulates Glucose and Glutamate Transporters in Hypothalamic Astrocytes. Sci. Rep. 6, 23673; doi: 10.1038/srep23673 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/